YBX1 and esophageal squamous cell carcinoma: Our current study illustrates a novel molecular mechanism of m5C‐mediated oncogene activation during ESCC progression and provides a rationale for targeting the YBX1/m5C‐SMOX signaling axis for the treatment of ESCC.